stockrowKeros Therapeutics, Inc.
KROSKeros Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $244.1 million, up 6,775.0% from fiscal 2024.
- Revenue
- +120.2%
- EPS
- +494.4%
- Free cash flow
- +6.87%
Quarter to September 2026, against a year earlier
Follow KROS
Alert me
Keros Therapeutics, Inc. (KROS) Return on invested capital
Keros Therapeutics, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −233.2%, down 501.9 percentage points from fiscal 2025 (268.7%). Over the past ten years it has ranged from −9,963.7% (fiscal 2023) to 268.7% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 268.7% | 1,402.49 |
| FY2024 | −1,133.8% | 8,829.91 |
| FY2023 | −9,963.7% | (9,963.71) |
| FY2022 | 0.00% | 268.30 |
| FY2021 | −268.3% | (268.30) |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | — |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| PRQR ProQR Therapeutics N.V. compare | 0.00% |
| PYXS Pyxis Oncology, Inc. compare | 0.00% |
| CGEN Compugen Ltd. compare | 0.00% |
| RNA Atrium Therapeutics, Inc. compare | 0.00% |
| IFRX InflaRx N.V. compare | −87.3% |
| ACOG Alpha Cognition Inc. compare | −144.7% |
| KROS Keros Therapeutics, Inc. | −233.2% |
| BCYC Bicycle Therapeutics PLC Sponsored ADR compare | −279.8% |
| TRDA Entrada Therapeutics, Inc. compare | −2,009.0% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)